1. Home
  2. PRLHU vs NAMSW Comparison

PRLHU vs NAMSW Comparison

Compare PRLHU & NAMSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLHU
  • NAMSW
  • Stock Information
  • Founded
  • PRLHU N/A
  • NAMSW N/A
  • Country
  • PRLHU
  • NAMSW Netherlands
  • Employees
  • PRLHU N/A
  • NAMSW 29
  • Industry
  • PRLHU
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRLHU
  • NAMSW Health Care
  • Exchange
  • PRLHU NYSE
  • NAMSW Nasdaq
  • Market Cap
  • PRLHU N/A
  • NAMSW N/A
  • IPO Year
  • PRLHU N/A
  • NAMSW N/A
  • Fundamental
  • Price
  • PRLHU $10.66
  • NAMSW $9.00
  • Analyst Decision
  • PRLHU
  • NAMSW
  • Analyst Count
  • PRLHU 0
  • NAMSW 0
  • Target Price
  • PRLHU N/A
  • NAMSW N/A
  • AVG Volume (30 Days)
  • PRLHU N/A
  • NAMSW N/A
  • Earning Date
  • PRLHU N/A
  • NAMSW N/A
  • Dividend Yield
  • PRLHU N/A
  • NAMSW N/A
  • EPS Growth
  • PRLHU N/A
  • NAMSW N/A
  • EPS
  • PRLHU N/A
  • NAMSW N/A
  • Revenue
  • PRLHU N/A
  • NAMSW N/A
  • Revenue This Year
  • PRLHU N/A
  • NAMSW N/A
  • Revenue Next Year
  • PRLHU N/A
  • NAMSW N/A
  • P/E Ratio
  • PRLHU N/A
  • NAMSW N/A
  • Revenue Growth
  • PRLHU N/A
  • NAMSW N/A
  • 52 Week Low
  • PRLHU N/A
  • NAMSW N/A
  • 52 Week High
  • PRLHU N/A
  • NAMSW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PRLHU N/A
  • NAMSW 48.40
  • Support Level
  • PRLHU N/A
  • NAMSW $8.30
  • Resistance Level
  • PRLHU N/A
  • NAMSW $9.77
  • Average True Range (ATR)
  • PRLHU 0.00
  • NAMSW 0.41
  • MACD
  • PRLHU 0.00
  • NAMSW -0.10
  • Stochastic Oscillator
  • PRLHU 0.00
  • NAMSW 27.78

About PRLHU PEARL HOLDINGS ACQUISITION CORP UNIT 1 CL A & 1/2 WT EXP

Pearl Holdings Acquisition Corp is a blank check company.

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: